Posted On: 11/07/2014 7:46:56 AM
Post# of 63828
$AVXL bottom Pr $0.175
Neuronetrix has been selected by Anavex Life Sciences Corp.
to support the upcoming Phase 2a clinical trial for ANAVEX 2-73
Website
10-Q 8/13/14
Summary
Shares Outstanding5: 38.26M
Float: 23.70M
% Held by Insiders1: 24.33%
% Held by Institutions1: 0.70%
64 % sell before Pr
Headlines
Friday, November 7, 2014
Neuronetrix has been selected by Anavex Life Sciences Corp. to support the upcoming Phase 2a clinical trial for ANAVEX 2-73PR Newswire
Thursday, November 6, 2014
Anavex to Present at SeeThruEquity Investor Conference in New York CityGlobeNewswire
Monday, November 3, 2014
Anavex Receives Regulatory Approval to Initiate Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS for Alzheimer's DiseaseGlobeNewswire
Monday, October 27, 2014
Institutional Investor Lincoln Park Capital Increases Ownership in Anavex, Pays Over 25% Premium to MarketGlobeNewswire
Thursday, October 23, 2014
ANAVEX LIFE SCIENCES CORP. Files SEC form 8-K, Other Events, Unregistered Sale of Equity Securities, Financial StatemEDGAR Online
Monday, September 8, 2014
Anavex Supports Alzheimer's Foundation of America's 3rd Annual Concepts in Care Educational ConferenceGlobeNewswire
Wednesday, September 3, 2014
Anavex to Present at Rodman & Renshaw 16th Annual Global Investment ConferenceGlobeNewswire
Tuesday, August 26, 2014
Anavex Selects The Alfred Hospital in Melbourne, Australia as Lead Site for Phase 2a Alzheimer's Clinical TrialGlobeNewswire
Monday, August 25, 2014
ANAVEX LIFE SCIENCES CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and EEDGAR Online
Friday, August 22, 2014
ANAVEX LIFE SCIENCES CORP. FinancialsEDGAR Online Financials
Tuesday, August 19, 2014
Anavex Reports That Antidepressant Fluvoxamine Reduces Stress Through Sigma-1 ReceptorGlobeNewswire
Wednesday, August 13, 2014
Anavex Reports Fiscal Third Quarter 2014 Financial ResultsGlobeNewswire
ANAVEX LIFE SCIENCES CORP. Files SEC form 10-Q, Quarterly ReportEDGAR Onlin
Friday, May 30, 2014
ANAVEX LIFE SCIENCES CORP. Files SEC form 10-Q/A, Quarterly ReportEDGAR Online
Wednesday, May 14, 2014
ANAVEX LIFE SCIENCES CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExEDGAR Online
Wednesday, March 19, 2014
ANAVEX LIFE SCIENCES CORP. Files SEC form 8-K, Other Events, Creation of a Direct Financial Obligation or an ObligatiEDGAR Online
Friday, March 14, 2014
ANAVEX LIFE SCIENCES CORP. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online
Friday, March 7, 2014
Alzheimer's Research Stocks - Technical And Other Considerationsat Seeking Alpha
Monday, February 24, 2014
ANAVEX LIFE SCIENCES CORP. Files SEC form 8-K, Other EventsEDGAR Online
Friday, February 14, 2014
ANAVEX LIFE SCIENCES CORP. Files SEC form 10-Q, Quarterly ReportEDGAR Online
Neuronetrix has been selected by Anavex Life Sciences Corp.
to support the upcoming Phase 2a clinical trial for ANAVEX 2-73
Website
10-Q 8/13/14
Summary
Shares Outstanding5: 38.26M
Float: 23.70M
% Held by Insiders1: 24.33%
% Held by Institutions1: 0.70%
64 % sell before Pr
Headlines
Friday, November 7, 2014
Neuronetrix has been selected by Anavex Life Sciences Corp. to support the upcoming Phase 2a clinical trial for ANAVEX 2-73PR Newswire
Thursday, November 6, 2014
Anavex to Present at SeeThruEquity Investor Conference in New York CityGlobeNewswire
Monday, November 3, 2014
Anavex Receives Regulatory Approval to Initiate Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS for Alzheimer's DiseaseGlobeNewswire
Monday, October 27, 2014
Institutional Investor Lincoln Park Capital Increases Ownership in Anavex, Pays Over 25% Premium to MarketGlobeNewswire
Thursday, October 23, 2014
ANAVEX LIFE SCIENCES CORP. Files SEC form 8-K, Other Events, Unregistered Sale of Equity Securities, Financial StatemEDGAR Online
Monday, September 8, 2014
Anavex Supports Alzheimer's Foundation of America's 3rd Annual Concepts in Care Educational ConferenceGlobeNewswire
Wednesday, September 3, 2014
Anavex to Present at Rodman & Renshaw 16th Annual Global Investment ConferenceGlobeNewswire
Tuesday, August 26, 2014
Anavex Selects The Alfred Hospital in Melbourne, Australia as Lead Site for Phase 2a Alzheimer's Clinical TrialGlobeNewswire
Monday, August 25, 2014
ANAVEX LIFE SCIENCES CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and EEDGAR Online
Friday, August 22, 2014
ANAVEX LIFE SCIENCES CORP. FinancialsEDGAR Online Financials
Tuesday, August 19, 2014
Anavex Reports That Antidepressant Fluvoxamine Reduces Stress Through Sigma-1 ReceptorGlobeNewswire
Wednesday, August 13, 2014
Anavex Reports Fiscal Third Quarter 2014 Financial ResultsGlobeNewswire
ANAVEX LIFE SCIENCES CORP. Files SEC form 10-Q, Quarterly ReportEDGAR Onlin
Friday, May 30, 2014
ANAVEX LIFE SCIENCES CORP. Files SEC form 10-Q/A, Quarterly ReportEDGAR Online
Wednesday, May 14, 2014
ANAVEX LIFE SCIENCES CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExEDGAR Online
Wednesday, March 19, 2014
ANAVEX LIFE SCIENCES CORP. Files SEC form 8-K, Other Events, Creation of a Direct Financial Obligation or an ObligatiEDGAR Online
Friday, March 14, 2014
ANAVEX LIFE SCIENCES CORP. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online
Friday, March 7, 2014
Alzheimer's Research Stocks - Technical And Other Considerationsat Seeking Alpha
Monday, February 24, 2014
ANAVEX LIFE SCIENCES CORP. Files SEC form 8-K, Other EventsEDGAR Online
Friday, February 14, 2014
ANAVEX LIFE SCIENCES CORP. Files SEC form 10-Q, Quarterly ReportEDGAR Online
(0)
(0)
